English
简体中文
Total: £ 56.28
Published Date: 2026-04-08 | Pages: 112 | Tables: 108 | Pharma & Healthcare
The global Nasal Spray Live Attenuated Vaccine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Nasal Spray Live Attenuated Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Nasal spray live attenuated vaccine is a live attenuated viral vaccine administered by nasal spray for the prevention of infection against specific diseases. This vaccine injects a weakened live virus into the body through the nasal mucosal route, which activates the immune system to produce a protective immune response against the disease.
The North American market for Nasal Spray Live Attenuated Vaccine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Nasal Spray Live Attenuated Vaccine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Nasal Spray Live Attenuated Vaccine include AstraZeneca, Sanofi, CSL, BioDiem, SEQIRUS, INC., Changchun BCHT Biotechnology Co., Serum Institute, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Nasal Spray Live Attenuated Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nasal Spray Live Attenuated Vaccine. The Nasal Spray Live Attenuated Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Nasal Spray Live Attenuated Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nasal Spray Live Attenuated Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZeneca
Sanofi
CSL
BioDiem
SEQIRUS, INC.
Changchun BCHT Biotechnology Co.
Serum Institute
Segment by Type
Trivalent Nasal Spray Live Attenuated Vaccine
Quadrivalent Nasal Spray Live Attenuated Vaccine
by Application
Hospitals & Clinics
Public Health Organizations
Research Organizations
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Nasal Spray Live Attenuated Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Nasal Spray Live Attenuated Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Nasal Spray Live Attenuated Vaccine Market Overview
1.1 Product Definition
1.2 Nasal Spray Live Attenuated Vaccine by Type
1.2.1 Global Nasal Spray Live Attenuated Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Trivalent Nasal Spray Live Attenuated Vaccine
1.2.3 Quadrivalent Nasal Spray Live Attenuated Vaccine
1.3 Nasal Spray Live Attenuated Vaccine by Application
1.3.1 Global Nasal Spray Live Attenuated Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Hospitals & Clinics
1.3.3 Public Health Organizations
1.3.4 Research Organizations
1.3.5 Others
1.4 Global Nasal Spray Live Attenuated Vaccine Market Size Estimates and Forecasts
1.4.1 Global Nasal Spray Live Attenuated Vaccine Revenue 2021–2032
1.4.2 Global Nasal Spray Live Attenuated Vaccine Sales 2021–2032
1.4.3 Global Nasal Spray Live Attenuated Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Nasal Spray Live Attenuated Vaccine Market Competition by Manufacturers
2.1 Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Nasal Spray Live Attenuated Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Nasal Spray Live Attenuated Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Nasal Spray Live Attenuated Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Nasal Spray Live Attenuated Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Nasal Spray Live Attenuated Vaccine, Date of Entry into the Industry
2.8 Global Nasal Spray Live Attenuated Vaccine Market Competitive Situation and Trends
2.8.1 Global Nasal Spray Live Attenuated Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Nasal Spray Live Attenuated Vaccine Players Market Share by Revenue
2.8.3 Global Nasal Spray Live Attenuated Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nasal Spray Live Attenuated Vaccine Market Scenario by Region
3.1 Global Nasal Spray Live Attenuated Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Nasal Spray Live Attenuated Vaccine Sales by Region: 2021–2032
3.2.1 Global Nasal Spray Live Attenuated Vaccine Sales by Region: 2021–2026
3.2.2 Global Nasal Spray Live Attenuated Vaccine Sales by Region: 2027–2032
3.3 Global Nasal Spray Live Attenuated Vaccine Revenue by Region: 2021–2032
3.3.1 Global Nasal Spray Live Attenuated Vaccine Revenue by Region: 2021–2026
3.3.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Region: 2027–2032
3.4 North America Nasal Spray Live Attenuated Vaccine Market Facts & Figures by Country
3.4.1 North America Nasal Spray Live Attenuated Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Nasal Spray Live Attenuated Vaccine Sales by Country (2021–2032)
3.4.3 North America Nasal Spray Live Attenuated Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nasal Spray Live Attenuated Vaccine Market Facts & Figures by Country
3.5.1 Europe Nasal Spray Live Attenuated Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Nasal Spray Live Attenuated Vaccine Sales by Country (2021–2032)
3.5.3 Europe Nasal Spray Live Attenuated Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nasal Spray Live Attenuated Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Nasal Spray Live Attenuated Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Nasal Spray Live Attenuated Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Nasal Spray Live Attenuated Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nasal Spray Live Attenuated Vaccine Market Facts & Figures by Country
3.7.1 Latin America Nasal Spray Live Attenuated Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Nasal Spray Live Attenuated Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Nasal Spray Live Attenuated Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nasal Spray Live Attenuated Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Nasal Spray Live Attenuated Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nasal Spray Live Attenuated Vaccine Sales by Type (2021–2032)
4.1.1 Global Nasal Spray Live Attenuated Vaccine Sales by Type (2021–2026)
4.1.2 Global Nasal Spray Live Attenuated Vaccine Sales by Type (2027–2032)
4.1.3 Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2021–2032)
4.2.1 Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2021–2026)
4.2.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2027–2032)
4.2.3 Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Nasal Spray Live Attenuated Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Nasal Spray Live Attenuated Vaccine Sales by Application (2021–2032)
5.1.1 Global Nasal Spray Live Attenuated Vaccine Sales by Application (2021–2026)
5.1.2 Global Nasal Spray Live Attenuated Vaccine Sales by Application (2027–2032)
5.1.3 Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2021–2032)
5.2.1 Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2021–2026)
5.2.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2027–2032)
5.2.3 Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Nasal Spray Live Attenuated Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca Nasal Spray Live Attenuated Vaccine Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sanofi Nasal Spray Live Attenuated Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 CSL
6.3.1 CSL Company Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 CSL Nasal Spray Live Attenuated Vaccine Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 BioDiem
6.4.1 BioDiem Company Information
6.4.2 BioDiem Description and Business Overview
6.4.3 BioDiem Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 BioDiem Nasal Spray Live Attenuated Vaccine Product Portfolio
6.4.5 BioDiem Recent Developments/Updates
6.5 SEQIRUS, INC.
6.5.1 SEQIRUS, INC. Company Information
6.5.2 SEQIRUS, INC. Description and Business Overview
6.5.3 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Product Portfolio
6.5.5 SEQIRUS, INC. Recent Developments/Updates
6.6 Changchun BCHT Biotechnology Co.
6.6.1 Changchun BCHT Biotechnology Co. Company Information
6.6.2 Changchun BCHT Biotechnology Co. Description and Business Overview
6.6.3 Changchun BCHT Biotechnology Co. Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Changchun BCHT Biotechnology Co. Nasal Spray Live Attenuated Vaccine Product Portfolio
6.6.5 Changchun BCHT Biotechnology Co. Recent Developments/Updates
6.7 Serum Institute
6.7.1 Serum Institute Company Information
6.7.2 Serum Institute Description and Business Overview
6.7.3 Serum Institute Nasal Spray Live Attenuated Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Serum Institute Nasal Spray Live Attenuated Vaccine Product Portfolio
6.7.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nasal Spray Live Attenuated Vaccine Industry Chain Analysis
7.2 Nasal Spray Live Attenuated Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nasal Spray Live Attenuated Vaccine Production Mode & Process Analysis
7.4 Nasal Spray Live Attenuated Vaccine Sales and Marketing
7.4.1 Nasal Spray Live Attenuated Vaccine Sales Channels
7.4.2 Nasal Spray Live Attenuated Vaccine Distributors
7.5 Nasal Spray Live Attenuated Vaccine Customer Analysis
8 Nasal Spray Live Attenuated Vaccine Market Dynamics
8.1 Nasal Spray Live Attenuated Vaccine Industry Trends
8.2 Nasal Spray Live Attenuated Vaccine Market Drivers
8.3 Nasal Spray Live Attenuated Vaccine Market Challenges
8.4 Nasal Spray Live Attenuated Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Nasal Spray Live Attenuated Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Nasal Spray Live Attenuated Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Nasal Spray Live Attenuated Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Nasal Spray Live Attenuated Vaccine Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Nasal Spray Live Attenuated Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Nasal Spray Live Attenuated Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Nasal Spray Live Attenuated Vaccine Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Nasal Spray Live Attenuated Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Nasal Spray Live Attenuated Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Nasal Spray Live Attenuated Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Nasal Spray Live Attenuated Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Nasal Spray Live Attenuated Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nasal Spray Live Attenuated Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Nasal Spray Live Attenuated Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Nasal Spray Live Attenuated Vaccine Sales by Region (K Dose), 2021–2026
Table 18. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Nasal Spray Live Attenuated Vaccine Sales by Region (K Dose), 2027–2032
Table 20. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Nasal Spray Live Attenuated Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Nasal Spray Live Attenuated Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Nasal Spray Live Attenuated Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2021–2026
Table 27. North America Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2027–2032
Table 28. North America Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Nasal Spray Live Attenuated Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2021–2026
Table 32. Europe Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2027–2032
Table 33. Europe Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Nasal Spray Live Attenuated Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Nasal Spray Live Attenuated Vaccine Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Nasal Spray Live Attenuated Vaccine Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Nasal Spray Live Attenuated Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Nasal Spray Live Attenuated Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Nasal Spray Live Attenuated Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2021–2026
Table 42. Latin America Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2027–2032
Table 43. Latin America Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Type (2021–2026)
Table 51. Global Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Type (2027–2032)
Table 52. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Nasal Spray Live Attenuated Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Nasal Spray Live Attenuated Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Nasal Spray Live Attenuated Vaccine Price (US$/Dose) by Type (2021–2026)
Table 59. Global Nasal Spray Live Attenuated Vaccine Price (US$/Dose) by Type (2027–2032)
Table 60. Global Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Application (2021–2026)
Table 61. Global Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Application (2027–2032)
Table 62. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Nasal Spray Live Attenuated Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Nasal Spray Live Attenuated Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Nasal Spray Live Attenuated Vaccine Price (US$/Dose) by Application (2021–2026)
Table 69. Global Nasal Spray Live Attenuated Vaccine Price (US$/Dose) by Application (2027–2032)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. AstraZeneca Nasal Spray Live Attenuated Vaccine Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Sanofi Nasal Spray Live Attenuated Vaccine Product
Table 79. Sanofi Recent Developments/Updates
Table 80. CSL Company Information
Table 81. CSL Description and Business Overview
Table 82. CSL Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. CSL Nasal Spray Live Attenuated Vaccine Product
Table 84. CSL Recent Developments/Updates
Table 85. BioDiem Company Information
Table 86. BioDiem Description and Business Overview
Table 87. BioDiem Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. BioDiem Nasal Spray Live Attenuated Vaccine Product
Table 89. BioDiem Recent Developments/Updates
Table 90. SEQIRUS, INC. Company Information
Table 91. SEQIRUS, INC. Description and Business Overview
Table 92. SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Product
Table 94. SEQIRUS, INC. Recent Developments/Updates
Table 95. Changchun BCHT Biotechnology Co. Company Information
Table 96. Changchun BCHT Biotechnology Co. Description and Business Overview
Table 97. Changchun BCHT Biotechnology Co. Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Changchun BCHT Biotechnology Co. Nasal Spray Live Attenuated Vaccine Product
Table 99. Changchun BCHT Biotechnology Co. Recent Developments/Updates
Table 100. Serum Institute Company Information
Table 101. Serum Institute Description and Business Overview
Table 102. Serum Institute Nasal Spray Live Attenuated Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Serum Institute Nasal Spray Live Attenuated Vaccine Product
Table 104. Serum Institute Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Nasal Spray Live Attenuated Vaccine Distributors List
Table 108. Nasal Spray Live Attenuated Vaccine Customers List
Table 109. Nasal Spray Live Attenuated Vaccine Market Trends
Table 110. Nasal Spray Live Attenuated Vaccine Market Drivers
Table 111. Nasal Spray Live Attenuated Vaccine Market Challenges
Table 112. Nasal Spray Live Attenuated Vaccine Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nasal Spray Live Attenuated Vaccine
Figure 2. Global Nasal Spray Live Attenuated Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Nasal Spray Live Attenuated Vaccine Market Share by Type: 2025 & 2032
Figure 4. Trivalent Nasal Spray Live Attenuated Vaccine Product Picture
Figure 5. Quadrivalent Nasal Spray Live Attenuated Vaccine Product Picture
Figure 6. Global Nasal Spray Live Attenuated Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Nasal Spray Live Attenuated Vaccine Market Share by Application: 2025 & 2032
Figure 8. Hospitals & Clinics
Figure 9. Public Health Organizations
Figure 10. Research Organizations
Figure 11. Others
Figure 12. Global Nasal Spray Live Attenuated Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Nasal Spray Live Attenuated Vaccine Market Size (US$ Million), 2021–2032
Figure 14. Global Nasal Spray Live Attenuated Vaccine Sales (K Dose), 2021–2032
Figure 15. Global Nasal Spray Live Attenuated Vaccine Average Price (US$/Dose), 2021–2032
Figure 16. Nasal Spray Live Attenuated Vaccine Report Years Considered
Figure 17. Nasal Spray Live Attenuated Vaccine Sales Share by Manufacturers in 2025
Figure 18. Global Nasal Spray Live Attenuated Vaccine Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Nasal Spray Live Attenuated Vaccine Players: Market Share by Revenue in Nasal Spray Live Attenuated Vaccine in 2025
Figure 20. Nasal Spray Live Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Nasal Spray Live Attenuated Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Nasal Spray Live Attenuated Vaccine Sales Market Share by Country (2021–2032)
Figure 23. North America Nasal Spray Live Attenuated Vaccine Revenue Market Share by Country (2021–2032)
Figure 24. United States Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Nasal Spray Live Attenuated Vaccine Sales Market Share by Country (2021–2032)
Figure 27. Europe Nasal Spray Live Attenuated Vaccine Revenue Market Share by Country (2021–2032)
Figure 28. Germany Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Nasal Spray Live Attenuated Vaccine Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Nasal Spray Live Attenuated Vaccine Revenue Market Share by Region (2021–2032)
Figure 35. China Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Nasal Spray Live Attenuated Vaccine Sales Market Share by Country (2021–2032)
Figure 43. Latin America Nasal Spray Live Attenuated Vaccine Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Nasal Spray Live Attenuated Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Nasal Spray Live Attenuated Vaccine by Type (2021–2032)
Figure 54. Global Revenue Market Share of Nasal Spray Live Attenuated Vaccine by Type (2021–2032)
Figure 55. Global Nasal Spray Live Attenuated Vaccine Price (US$/Dose) by Type (2021–2032)
Figure 56. Global Sales Market Share of Nasal Spray Live Attenuated Vaccine by Application (2021–2032)
Figure 57. Global Revenue Market Share of Nasal Spray Live Attenuated Vaccine by Application (2021–2032)
Figure 58. Global Nasal Spray Live Attenuated Vaccine Price (US$/Dose) by Application (2021–2032)
Figure 59. Nasal Spray Live Attenuated Vaccine Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
